- Home
- AUDC vs IMMP Comparison
AUDC vs IMMP Comparison
Compare AUDC & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUDC
- IMMP
- Stock Information
- Founded
- AUDC 1992
- IMMP 1987
- Country
- AUDC Israel
- IMMP Australia
- Employees
- AUDC N/A
- IMMP N/A
- Industry
- AUDC Telecommunications Equipment
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- AUDC Utilities
- IMMP Health Care
- Exchange
- AUDC Nasdaq
- IMMP Nasdaq
- Market Cap
- AUDC 279.1M
- IMMP 211.1M
- IPO Year
- AUDC 1999
- IMMP N/A
- Fundamental
- Price
- AUDC $8.44
- IMMP $1.86
- Analyst Decision
- AUDC Buy
- IMMP Buy
- Analyst Count
- AUDC 3
- IMMP 2
- Target Price
- AUDC $11.67
- IMMP $8.50
- AVG Volume (30 Days)
- AUDC 109.7K
- IMMP 648.0K
- Earning Date
- AUDC 05-06-2025
- IMMP 05-16-2025
- Dividend Yield
- AUDC 2.13%
- IMMP N/A
- EPS Growth
- AUDC 57.57
- IMMP N/A
- EPS
- AUDC 0.56
- IMMP N/A
- Revenue
- AUDC $242,474,000.00
- IMMP $3,019,249.00
- Revenue This Year
- AUDC $5.11
- IMMP $11.25
- Revenue Next Year
- AUDC $3.81
- IMMP $10.22
- P/E Ratio
- AUDC $15.02
- IMMP N/A
- Revenue Growth
- AUDC N/A
- IMMP 24.11
- 52 Week Low
- AUDC $7.70
- IMMP $1.32
- 52 Week High
- AUDC $12.72
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- AUDC 35.54
- IMMP 53.43
- Support Level
- AUDC $8.01
- IMMP $1.44
- Resistance Level
- AUDC $9.84
- IMMP $2.71
- Average True Range (ATR)
- AUDC 0.31
- IMMP 0.17
- MACD
- AUDC -0.06
- IMMP 0.05
- Stochastic Oscillator
- AUDC 23.50
- IMMP 29.75
About AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells onverged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.